Medistim ASA (MD1) Ratios
Medistim ASA Ratios
DE:MD1's free cash flow for Q3 2026 was $0.00. For the 2026 fiscal year, DE:MD1's free cash flow was decreased by $-91.47M and operating cash flow was $91.47M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.34 | 4.00 | 4.15 | 3.87 | 3.95 |
| Quick Ratio | 2.21 | 2.50 | 2.61 | 2.72 | 2.69 |
| Cash Ratio | 1.48 | 1.67 | 1.63 | 1.44 | 1.61 |
| Solvency Ratio | 0.95 | 0.93 | 1.18 | 1.14 | 1.11 |
| Operating Cash Flow Ratio | 1.31 | 1.33 | 1.20 | 1.14 | 1.65 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 285.53M | $ 290.77M | $ 283.79M | $ 270.93M | $ 209.31M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.06 | 0.03 | 0.04 | 0.06 |
| Debt-to-Equity Ratio | 0.11 | 0.08 | 0.04 | 0.05 | 0.08 |
| Debt-to-Capital Ratio | 0.10 | 0.07 | 0.04 | 0.04 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.41 | 1.32 | 1.27 | 1.31 | 1.32 |
| Debt Service Coverage Ratio | 29.52 | 272.70 | 215.90 | 342.06 | 184.50 |
| Interest Coverage Ratio | 30.78 | 285.57 | 229.39 | 366.89 | 197.08 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.04 | 1.90 | 0.99 | 0.96 | 1.36 |
| Net Debt to EBITDA | -0.69 | -0.93 | -0.88 | -0.78 | -0.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 45.90% | 79.79% | 78.45% | 78.10% | 76.76% |
| EBIT Margin | 30.45% | 23.30% | 25.22% | 30.11% | 27.44% |
| EBITDA Margin | 33.69% | 27.65% | 29.76% | 33.68% | 31.60% |
| Operating Profit Margin | 28.04% | 23.30% | 25.22% | 29.05% | 27.83% |
| Pretax Profit Margin | 29.56% | 23.86% | 25.95% | 30.04% | 27.30% |
| Net Profit Margin | 22.75% | 18.46% | 19.92% | 23.44% | 21.76% |
| Continuous Operations Profit Margin | 22.75% | 18.46% | 19.92% | 23.44% | 21.76% |
| Net Income Per EBT | 76.97% | 77.34% | 76.79% | 78.04% | 79.69% |
| EBT Per EBIT | 105.43% | 102.42% | 102.87% | 103.40% | 98.10% |
| Return on Assets (ROA) | 24.10% | 18.06% | 20.53% | 23.61% | 22.54% |
| Return on Equity (ROE) | 33.99% | 23.78% | 26.09% | 31.00% | 29.70% |
| Return on Capital Employed (ROCE) | 37.92% | 28.03% | 31.95% | 36.90% | 35.71% |
| Return on Invested Capital (ROIC) | 28.55% | 21.26% | 24.04% | 28.27% | 27.85% |
| Return on Tangible Assets | 27.71% | 20.14% | 22.55% | 25.52% | 24.37% |
| Earnings Yield | 3.36% | 3.79% | 2.65% | 2.70% | 1.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.70 | 7.21 | 7.01 | 4.61 | 5.68 |
| Payables Turnover | 14.22 | 6.41 | 4.48 | 4.35 | 7.35 |
| Inventory Turnover | 2.35 | 0.71 | 0.77 | 0.93 | 1.00 |
| Fixed Asset Turnover | 7.99 | 7.69 | 9.09 | 9.48 | 7.10 |
| Asset Turnover | 1.06 | 0.98 | 1.03 | 1.01 | 1.04 |
| Working Capital Turnover Ratio | 2.13 | 1.82 | 1.79 | 1.89 | 2.01 |
| Cash Conversion Cycle | 184.19 | 509.10 | 443.14 | 387.23 | 380.72 |
| Days of Sales Outstanding | 54.51 | 50.63 | 52.04 | 79.21 | 64.22 |
| Days of Inventory Outstanding | 155.35 | 515.39 | 472.64 | 391.90 | 366.12 |
| Days of Payables Outstanding | 25.67 | 56.93 | 81.54 | 83.88 | 49.63 |
| Operating Cycle | 209.86 | 566.02 | 524.68 | 471.11 | 430.35 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 10.24 | 7.81 | 6.18 | 6.22 | 7.03 |
| Free Cash Flow Per Share | 9.94 | 7.48 | 4.56 | 5.06 | 6.40 |
| Dividend Paid and CapEx Coverage Ratio | 1.63 | 1.62 | 1.01 | 1.27 | 1.94 |
| Capital Expenditure Coverage Ratio | 34.06 | 23.58 | 3.81 | 5.38 | 11.16 |
| Operating Cash Flow Coverage Ratio | 3.80 | 4.16 | 6.42 | 6.63 | 5.30 |
| Operating Cash Flow to Sales Ratio | 0.27 | 0.25 | 0.22 | 0.23 | 0.31 |
| Free Cash Flow Yield | 3.84% | 5.01% | 2.13% | 2.19% | 1.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.74 | 26.37 | 37.74 | 36.98 | 73.65 |
| Price-to-Sales (P/S) Ratio | 6.76 | 4.87 | 7.52 | 8.67 | 16.02 |
| Price-to-Book (P/B) Ratio | 10.11 | 6.27 | 9.85 | 11.46 | 21.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 26.07 | 19.98 | 46.95 | 45.62 | 57.39 |
| Price-to-Operating Cash Flow Ratio | 25.30 | 19.13 | 34.62 | 37.14 | 52.24 |
| Price-to-Earnings Growth (PEG) Ratio | 0.55 | 0.00 | -4.07 | 1.46 | 2.38 |
| Enterprise Value Multiple | 19.39 | 16.67 | 24.39 | 24.96 | 49.94 |
| Enterprise Value | 4.57B | 2.59B | 3.78B | 4.09B | 6.59B |
| EV to EBITDA | 19.39 | 16.67 | 24.39 | 24.96 | 49.94 |
| EV to Sales | 6.53 | 4.61 | 7.26 | 8.41 | 15.78 |
| EV to Free Cash Flow | 25.17 | 18.92 | 45.32 | 44.25 | 56.52 |
| EV to Operating Cash Flow | 24.43 | 18.12 | 33.42 | 36.02 | 51.46 |
| Tangible Book Value Per Share | 20.92 | 20.60 | 19.25 | 18.17 | 15.15 |
| Shareholders’ Equity Per Share | 25.63 | 23.84 | 21.73 | 20.15 | 16.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.23 | 0.23 | 0.22 | 0.20 |
| Revenue Per Share | 38.29 | 30.72 | 28.46 | 26.65 | 22.94 |
| Net Income Per Share | 8.71 | 5.67 | 5.67 | 6.25 | 4.99 |
| Tax Burden | 0.77 | 0.77 | 0.77 | 0.78 | 0.80 |
| Interest Burden | 0.97 | 1.02 | 1.03 | 1.00 | 0.99 |
| Research & Development to Revenue | 0.06 | 0.06 | 0.03 | 0.03 | 0.03 |
| SG&A to Revenue | 0.09 | 0.11 | 0.28 | 0.06 | 0.07 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.18 | 1.38 | 1.09 | 1.00 | 1.41 |
Currency in NOK
